CLAIMS

1. A morphic form of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile ("Compound A"), wherein the morphic form is a hydrate.

2. The morphic form of claim 1, wherein the hydrate is monohydrate.

3. The morphic form of claim 1, wherein the hydrate is a dihydrate.

4. A pharmaceutical composition comprising the morphic form of claim 3 and a pharmaceutically acceptable carrier.

5. The morphic form of any one of claims 1 to 3 or the pharmaceutical composition of claim 4, for use in medicine.

6. Use of the morphic form of claim 3 in the preparation of a pharmaceutical composition for treating a resistance to thyroid hormone (RTH) syndrome in a subject having at least one TRβ mutation, wherein a therapeutically effective amount of the morphic form of claim 3 is to be administered to the subject.

7. The use of claim 6, wherein the subject has a disease or disorder selected from the group consisting of fatty liver disease, attention deficit hyperactivity disorder, a learning disability, thyroid axis alteration, atherosclerosis, a cardiovascular disorder, tachycardia, hyperkinetic behavior, hypothyroidism, goiter, hearing loss, delayed bone age, and thyroid cancer.

8. The use of claim 7, wherein the disease or disorder is selected from the group consisting of fatty liver disease, attention deficit hyperactivity disorder, a learning disability, atherosclerosis, and a cardiovascular disorder.

9. The use of claim 6, wherein the TRβ mutation is selected from the group consisting of a substitution of threonine (T) for the wild type residue alanine (A) at amino acid position 234 of SEQ ID NO: 1 (A234T); a substitution of glutamine (Q) for the wild type residue arginine (R) at amino acid position 243 of SEQ ID NO: 1 (R243Q); a substitution of histidine (H) for the wild type residue arginine (R) at amino acid position 316 of SEQ ID NO: 1 (R316H); and a substitution of threonine (T) for the wild type residue alanine (A) at amino acid position 317 of SEQ ID NO: 1 (A317T).

10. The use of claim 6, wherein the morphic form has a purity of Compound A of 95% or greater.

11. Use of the morphic form of claim 3 in the preparation of a pharmaceutical composition for treating nonalcoholic steatohepatitis in a subject in need thereof, wherein a therapeutically effective amount of the morphic form of claim 3 is to be administered to the subject.

12. The use of claim 11, wherein the morphic form has a purity of Compound A of 95% or greater.

13. Use of the morphic form of claim 3 in the preparation of a pharmaceutical composition for treating hypercholesterolemia in a subject in need thereof, wherein a therapeutically effective amount of the morphic form of claim 3 is to be administered to the subject.

14. The use of claim 13, wherein the morphic form has a purity of Compound A of 95% or greater.

15. Use of the morphic form of claim 3 in the preparation of a pharmaceutical composition for treating fatty liver disease in a subject in need thereof, wherein a therapeutically effective amount of the morphic form of claim 3 is to be administered to the subejct.

16. The use of claim 15, wherein the morphic form has a purity of Compound A of 95% or greater.